Arcutis Biotherapeutics Gets FDA Approval for Atopic Dermatitis Supplemental NDA
By Sabela Ojea
Arcutis Biotherapeutics said the U.S. Food and Administration has approved its supplemental new drug application for Zoryve cream to treat mild to moderate atopic dermatitis.
The commercial-stage biopharmaceutical company on Tuesday said the cream has been approved for adult and pediatric patients age six and older.
Zoryve rapidly improves and controls disease, including itch, the most bothersome reported symptom, the company said.
Atopic dermatitis is the most common form of eczema, affecting 9.6 million children and 16.5 million adults in the U.S.
Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix
(END) Dow Jones Newswires
July 09, 2024 17:32 ET (21:32 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
Undervalued by 25% and Yielding 5%, This Stock Is a Buy
-
Can AI Predict Future Stock Returns?
-
The Best Energy Stocks to Buy Now
-
10 Undervalued Wide-Moat Stocks
-
Obesity Drugs: Can New Firms Take Market Share From Eli Lilly and Novo Nordisk?
-
New 4-Star Stocks
-
Intel Fair Value Left Unchanged Despite Qualcomm Takeover Talk